Up-to-date commercial intelligence about business opportunities in the #global #generic #medicines and #biosimilars markets

Joined September 2010
Regulatory Recap: US Senate Passes Anti-Patent Thicket Bill, EU Council Debates Pharma Package bit.ly/3Lu3O9R
161
Entering The GGB Awards: One Week To Go! bit.ly/4faY0zS
137
J&J Confirms EU Stelara Biosimilars Are Imminent bit.ly/3Sd3xfe
124
Xbrane Inching Closer To Cimzia Biosimilar Trials With Batch Production bit.ly/3Y9t5Of
1
222
Zydus’s ‘Transparency Failure’ Leads To Block On Indian Perjeta Biosimilar bit.ly/4eZYzMV
64
Hyloris Replaces Leadership After Continued Transaction Woes bit.ly/3y1d9TG
70
Biosimilars Report Bolsters IGBA’s Calls To Streamline Development Process bit.ly/4cHq77U
2
2
111
Generics Bulletin Explains: After Humira Biosimilars, Will It Be Groundhog Day For Stelara? bit.ly/3W74Ai8
60
UK Prices Continue To Shoot Up In June bit.ly/4f5Xzqg
37
Fresenius Follows US Denosumab Filing With EU Acceptance bit.ly/3LuNi9v
49
ANI Acquires Alimera Sciences To Bolster Ophthalmology Portfolio bit.ly/3VTrNUQ
34
PBMs Hinder Access To Generics And Biosimilars, Finds FTC’s Investigation bit.ly/4f2Zhci
40
Cipla’s Verma Succeeds Kabi US Veteran Ducker As CEO bit.ly/3LlkOiz
71
Apotex Secures Canadian License For Loqtorzi From Coherus bit.ly/4eRTWo5
1
126
AEON Aims For Biosimilar Pathway For Lead Candidate In Cervical Dystonia bit.ly/3LlksbE
53
South Africa Drops J&J Bedaquiline Scrutiny After Generic Market Opens Up bit.ly/3RYDGYv
48
Celltrion’s Xolair Biosimilar Reaches UK, Following Key US Filing bit.ly/4eQHTax
84